global developmental delay. Specific developmental disorder of motor function
Conditions
Interventions
In this study, 40 patients with developmental delay in more than or equal to 2 developmental areas are selected from among the patients referred to the pediatric neurology clinics and the Comprehensiv
Sponsors
Research Vice-chancellor
Eligibility
Sex/Gender
All
Age
2 Months to 5 Years
Inclusion criteria
Inclusion criteria: age below 5 years and above 2 months Developmental delay in more than or equal to two developmental domains
Exclusion criteria
Exclusion criteria: Having a metabolic disease or underlying structural disorder Lack of informed consent to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Improvement of performance in the area of ??fine movements 2) Improvement of performance in the area of ??gross movements 3) Improvement of performance in the area of ??communication 4) Improvement of performance in the area of ??problem-solving 5) Improvement of performance in the personal-social area. Timepoint: Evaluation of the developmental form of the ASQ at the beginning of the study, 3 months, and 6 months after the start of the drug. Method of measurement: The effect of Piracetam on improving the development of a person, which is evaluated by the ASQ developmental questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Bita Poorshiri
Tabriz University of Medical Sciences
Outcome results
None listed